ABSTRACT In patients with radiological evidence of pulmonary emphysema the bronchodilator drugs fenoterol and ipratropium bromide produced a considerable increase in vital capacity and reduction in residual volume. The response to fenoterol was virtually complete 15 minutes after administration, but after ipratropium bromide vital capacity was still increasing at 60 minutes. The change in vital capacity was slightly greater with a combination of the two drugs than with either used alone. Changes in FEV, and peak flow rate were small.
either used alone. Changes in FEV, and peak flow rate were small.
The anticholinergic ipratropium bromide and sympathomimetic agents such as fenoterol have been widely used for their bronchodilator properties in patients with bronchial asthma and other forms of airflow obstruction. '-3 It has been conventional to assess bronchodilator responsiveness by measurement of changes in peak expiratory flow rate or similar lung function indices, but in patients with emphysema any beneficial effects of bronchodilator treatment are largely associated with increase in the vital capacity.4 In patients with chronic airflow obstruction the combination of sympathomimetic and anticholinergic agents may confer an additional benefit.35 In this study we set out to assess the effects of fenoterol and ipratropium bromide, administered singly and in combination, on lung function in patients with definite evidence of pulmonary emphysema.
Patients and methods
Male patients with radiological evidence of pulmonary emphysema6 were selected for this study. No patient was taking oral or inhaled corticosteroids and all bronchodilator treatment was stopped 12 hours before the start of each day of study.
The trial was of double-blind crossover design, the treatments being given according to a randomisation schedule. The four treatments were as follows: (1) ipratropium bromide (40 ,ug) and placebo; (2) fenoterol (400 ,ug) and placebo; (3) ipratropium bromide (40 ug) and fenoterol (400 L&g); (4) placebo. Each treatment was administered by two puffs from each of two identical metered-dose inhalers, delivered successively and without delay. Treatments were not given on successive days.
Forced expiratory volume in 1 second (FEVy), relaxed vital capacity, and inspiratory capacity were measured with a Bernstein spirometer, and peak expiratory flow rate with a Wright's peak flow meter. Functional residual capacity was measured with a Collins 09001 body plethysmograph.
The patients rested for 15 minutes after arrival at the laboratory. Three baseline measurements of FEV,, vital capacity, and peak expiratory flow rate were made at 15-minute intervals, the largest being accepted as the baseline value. Baseline measurements of FRC (mean of six) were then obtained.
FEV,, vital capacity, and peak expiratory flow rate were measured again 15, 30, 60, and 90 minutes after inhalation of the test aerosols; functional residual capacity was again measured 45 minutes after inhalation, immediately preceded by measurement of vital capacity and inspiratory capacity for calculating residual volume and total lung capacity.
The changes in FEV,, vital capacity, and peak flow rate have been expressed as the difference between the observed value after treatment and the maximum pretreatment baseline value. All changes in lung function after the three "active" treatments, ipratropium bromide, fenoterol, and the combination of the two, were compared with the change after placebo alone and assessed statistically by analysis of variance; Duncan's fig 1) .
Lung volumes
Data on lung volumes are shown in figure 4 . Function residual capacity values showed a significantly greater fall after ipratropium and fenoterol (p < 0.05) than after placebo. The fall after the combined treatment was not significant (p < 0.01). Residual volume fell significantly more after ipratropium, fenoterol, and the combination of the two (p < 0.05) than after placebo, which was followed by no significant change. The was no significant change in total lung capacity on any of the four treatment days.
SIDE EFFECTS
There were fourteen reports of a bad or bitter taste after the test aerosol, four after ipratropium, three after fenoterol, five after the combined treatment, and two after placebo.
Discussion
In this study we have shown that in patients with radiological evidence of pulmonary emphysema the bronchodilator drugs fenoterol and ipratropium bromide (given by aerosol either singly or in combination) can produce significant changes in lung function indices. The greatest changes were seen in vital capacity, which increased on average by over 0*5 litre with all the active treatments; in some patients an increase of over a litre was achieved. The changes in FEV, and peak expiratory flow rate, though significant, were small. The dose of ipratropium (40 ,ug) used in this study would appear to be enough to produce a near-maximal response since Douglas et a13 obtained similar results using double this dose; they did, however, observe a further increase in FEV, and vital capacity when salbutamol was administered three hours after ipratropium.
There were clear-cut differences between the two drugs in the rates of change in the lung function indices that occurred after administration. With fenoterol alone, FEV, and vital capacity underwent no significant change after 15 minutes, nor did peak expiratory flow rate after 30 minutes; with ipratropium, on the other hand, all three indices appeared to be still increasing at 60 or 90 minutes. The combination, like ipratropium alone, produced a further rise after the 15-minute or 30-minute time-point; in general, for a given drug treatment (or combination) the time courses of these three lung function indices showed an obvious resemblance to each other (figs 1-3 In this study the increase in vital capacity was almost entirely at the expense of the residual volume, the total lung capacity undergoing little change, and a fall in functional residual capacity after ipratropium has also been shown in patients with chronic obstructive bronchitis.' 3 Subjective improvement after bronchodilator aerosol has been shown to be related to increase in vital capacity rather than FEV, or peak expiratory flow rate. 4 This beneficial effect is presumably due to the reduction in functional residual capacity that follows release of bronchomotor tone; thus tidal respiration can take place over a lower section of the pressure-volume curve of the respiratory system, where a given change in volume can be achieved for a smaller change in transpulmonary pressure.
